Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/30240% above fair value
$56.96−0.46 (-0.80%)
Close on Nov 13, 2026Market cap $2.92BP/E 96.5Yield –
Vericel operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vericel's operating cash flow for the twelve months ending Sep 30, 2026 was $65.31M, up 10.4% year over year. For fiscal 2025 it was $51.91M, down 10.8% from the year before. The highest annual figure on record is $58.16M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.91M | -10.8% |
| FY2024 | Dec 31, 2024 | $58.16M | +64.7% |
| FY2023 | Dec 31, 2023 | $35.31M | +99.6% |
| FY2022 | Dec 31, 2022 | $17.69M | -39.1% |
| FY2021 | Dec 31, 2021 | $29.04M | +65.3% |
| FY2020 | Dec 31, 2020 | $17.57M | – |
| FY2019 | Dec 31, 2019 | -$7.18M | – |
| FY2018 | Dec 31, 2018 | -$412.00K | – |
| FY2017 | Dec 31, 2017 | -$13.18M | – |
| FY2016 | Dec 31, 2016 | -$19.89M | – |
| FY2015 | Dec 31, 2015 | -$13.35M | – |
| FY2014 | Dec 31, 2014 | -$25.41M | – |
| FY2013 | Dec 31, 2013 | -$19.94M | – |
| FY2012 | Dec 31, 2012 | -$29.55M | – |
| FY2010 | Jun 30, 2010 | -$15.09M | – |
| FY2009 | Jun 30, 2009 | -$13.81M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.72M | -19.7% |
| Q2 FY2026 | Jun 30, 2026 | $16.19M | +97.1% |
| Q1 FY2026 | Mar 31, 2026 | $16.38M | +148.2% |
| Q4 FY2025 | Dec 31, 2025 | $15.01M | -32.5% |
| Q3 FY2025 | Sep 30, 2025 | $22.08M | +116.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.21M | -55.7% |
| Q1 FY2025 | Mar 31, 2025 | $6.60M | -8.4% |
| Q4 FY2024 | Dec 31, 2024 | $22.24M | +120.5% |
| Q3 FY2024 | Sep 30, 2024 | $10.18M | +42.1% |
| Q2 FY2024 | Jun 30, 2024 | $18.54M | +81.8% |
| Q1 FY2024 | Mar 31, 2024 | $7.20M | -8.4% |
| Q4 FY2023 | Dec 31, 2023 | $10.09M | +44.6% |
| Q3 FY2023 | Sep 30, 2023 | $7.17M | +74.8% |
| Q2 FY2023 | Jun 30, 2023 | $10.20M | +224.4% |
| Q1 FY2023 | Mar 31, 2023 | $7.86M | +126.6% |
| Q4 FY2022 | Dec 31, 2022 | $6.98M | -33.9% |
| Q3 FY2022 | Sep 30, 2022 | $4.10M | +12.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.14M | -34.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.47M | -65.6% |
| Q4 FY2021 | Dec 31, 2021 | $10.55M | -6.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.63M | -20.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.77M | – |
| Q1 FY2021 | Mar 31, 2021 | $10.09M | +115.2% |
| Q4 FY2020 | Dec 31, 2020 | $11.34M | +259.9% |
| Q3 FY2020 | Sep 30, 2020 | $4.57M | -42.1% |
| Q2 FY2020 | Jun 30, 2020 | -$3.02M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.69M | +2942.9% |
| Q4 FY2019 | Dec 31, 2019 | $3.15M | +20.6% |
| Q3 FY2019 | Sep 30, 2019 | $7.89M | +292.1% |
| Q2 FY2019 | Jun 30, 2019 | -$18.38M | – |
| Q1 FY2019 | Mar 31, 2019 | $154.00K | -62.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.61M | +213.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.44M | – |
| Q1 FY2018 | Mar 31, 2018 | $405.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $834.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.65M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.12M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.31M | – |
See a number that looks wrong?